|
TolerRx helps immune systems work on the virtue of tolerance. The company develops therapies to treat patients with autoimmune diseases, including Type I diabetes and rheumatoid arthritis. Organ transplant rejection is also a target. The company's treatments induce immunological tolerance, or teach a body's immune system to recognize its own tissues and prevent it from attacking the tissue and causing disease. TolerRx has five autoimmune and two cancer/chronic viral drugs in the pipeline. The immune drugs include treatments for Type I diabetes, psoriasis, rheumatoid arthritis, and lupus. TolerRx was founded in 2000 by Herman Waldmann and Douglas J. Ringler.
|
| | | Contact Information | |
Address: |
300 Technology Sq., 3rd Fl.
Cambridge, MA 02139
| | Phone: | 617-354-8100 | | Fax: | 617-354-8300 |
|
| Financial
Highlights | | Fiscal Year End: | December | | Revenue (2008): | 8.70 M | | Employees (2008): | 55 |
|
|
Key People
| | • |
Chairman:
Wayne T. Hockmeyer
| | • |
President, CEO, and Director:
Douglas J. Ringler
| | • |
CFO:
Thomas A. Shea
|
|
|
